Clinical trial
Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic…
NCT00411905 · Groupe Francophone des Myelodysplasies, Other · Completed
Key facts
| NCT number | NCT00411905 |
|---|---|
| Title | Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes |
| Official title | Phase I/II Study of Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes |
| Lead sponsor | Groupe Francophone des Myelodysplasies, Other |
| Collaborators | Johnson & Johnson Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Bortezomib |
| Enrollment | 45 |
| Start date | Jun 1, 2006 |
| Primary completion | Jul 8, 2010 |
| Completion | Aug 1, 2011 |
| First posted | Dec 15, 2006 |
| Last update posted | Jan 7, 2025 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: